Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Society for Pediatric Dermatology to hold virtual meeting » 10:18
07/10/20
07/10
10:18
07/10/20
10:18
ABEO

Abeona Therapeutics

$3.02 /

-0.33 (-9.85%)

, AMGN

Amgen

$247.24 /

-4.025 (-1.60%)

, DRMT

Dermavant

$0.00 /

+ (+0.00%)

, NVS

Novartis

$86.61 /

-0.71 (-0.81%)

, PFE

Pfizer

$33.69 /

+0.24 (+0.72%)

, SNY

Sanofi

$50.25 /

-0.31 (-0.61%)

, VRCA

Verrica Pharmaceuticals

$9.70 /

+0.94 (+10.73%)

45th Annual Virtual…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ABEO Abeona Therapeutics
$3.02 /

-0.33 (-9.85%)

AMGN Amgen
$247.24 /

-4.025 (-1.60%)

DRMT Dermavant
$0.00 /

+ (+0.00%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

PFE Pfizer
$33.69 /

+0.24 (+0.72%)

SNY Sanofi
$50.25 /

-0.31 (-0.61%)

VRCA Verrica Pharmaceuticals
$9.70 /

+0.94 (+10.73%)

ABEO Abeona Therapeutics
$3.02 /

-0.33 (-9.85%)

06/05/20 Cantor Fitzgerald
Abeona could trade higher on Lysogene clinical hold, says Cantor Fitzgerald
05/08/20 Jefferies
Abeona 'one of most underappreciated' in late-stage gene therapy, says Jefferies
12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
AMGN Amgen
$247.24 /

-4.025 (-1.60%)

07/02/20 Citi
Citi sees 'considerable amount of investor interest' coming back to Amgen
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Mizuho
Amgen patent win worth $5-$12 per share, says Mizuho
07/01/20 Goldman Sachs
Court ruling removes overhang for Amgen, says Goldman Sachs
DRMT Dermavant
$0.00 /

+ (+0.00%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
PFE Pfizer
$33.69 /

+0.24 (+0.72%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
SNY Sanofi
$50.25 /

-0.31 (-0.61%)

07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
06/26/20 SunTrust
Translate Bio initiated with a Buy at SunTrust
VRCA Verrica Pharmaceuticals
$9.70 /

+0.94 (+10.73%)

06/30/20 H.C. Wainwright
Verrica Pharmaceuticals price target lowered to $18 from $24 at H.C. Wainwright
06/24/20 Northland
Verrica Pharmaceuticals initiated with an Outperform at Northland
03/24/20
Fly Intel: Top five analyst initiations
03/24/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
ABEO Abeona Therapeutics
$3.02 /

-0.33 (-9.85%)

AMGN Amgen
$247.24 /

-4.025 (-1.60%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

PFE Pfizer
$33.69 /

+0.24 (+0.72%)

SNY Sanofi
$50.25 /

-0.31 (-0.61%)

VRCA Verrica Pharmaceuticals
$9.70 /

+0.94 (+10.73%)

  • 20
    Dec
AMGN Amgen
$247.24 /

-4.025 (-1.60%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

PFE Pfizer
$33.69 /

+0.24 (+0.72%)

SNY Sanofi
$50.25 /

-0.31 (-0.61%)

AMGN Amgen
$247.24 /

-4.025 (-1.60%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

PFE Pfizer
$33.69 /

+0.24 (+0.72%)

SNY Sanofi
$50.25 /

-0.31 (-0.61%)

VRCA Verrica Pharmaceuticals
$9.70 /

+0.94 (+10.73%)

AMGN Amgen
$247.24 /

-4.025 (-1.60%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

PFE Pfizer
$33.69 /

+0.24 (+0.72%)

SNY Sanofi
$50.25 /

-0.31 (-0.61%)

Conference/Events
International Aids Society to hold a virtual conference » 04:55
07/10/20
07/10
04:55
07/10/20
04:55
ABT

Abbott

$93.68 /

+1.11 (+1.20%)

, BDX

Becton Dickinson

$258.57 /

+5.92 (+2.34%)

, GILD

Gilead

$74.67 /

-0.96 (-1.27%)

, HOLX

Hologic

$57.45 /

-0.13 (-0.23%)

, MRK

Merck

$76.70 /

-1.17 (-1.50%)

, OSUR

OraSure

$13.86 /

+0.495 (+3.71%)

23rd International AIDS…

23rd International AIDS Virtual Conference: AIDS 2020 will be held on July 6-10. Webcast Link

ShowHide Related Items >><<
OSUR OraSure
$13.86 /

+0.495 (+3.71%)

MRK Merck
$76.70 /

-1.17 (-1.50%)

HOLX Hologic
$57.45 /

-0.13 (-0.23%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

BDX Becton Dickinson
$258.57 /

+5.92 (+2.34%)

ABT Abbott
$93.68 /

+1.11 (+1.20%)

ABT Abbott
$93.68 /

+1.11 (+1.20%)

07/01/20 Lake Street
Lake Street says Tandem pact with Abbott, coverage news both 'very positive'
06/15/20 Piper Sandler
Abbott approval narrows competitive gap to DexCom, says Piper Sandler
06/11/20 UBS
Abbott's COVID-19 testing positive contributor, says UBS
06/09/20 Barrington
Surmodics price target raised to $62 from $56 at Barrington
BDX Becton Dickinson
$258.57 /

+5.92 (+2.34%)

07/09/20
Fly Intel: Top five analyst upgrades
07/09/20 Barclays
Barclays upgrades Becton Dickinson to Overweight on 'window of opportunity'
07/09/20 Barclays
Becton Dickinson upgraded to Overweight from Equal Weight at Barclays
07/02/20 Wells Fargo
Becton rallies after Wells says rapid COVID test may come very soon
GILD Gilead
$74.67 /

-0.96 (-1.27%)

04:49 Today Stifel
Galapagos downgraded to Hold from Buy at Stifel
06/30/20 SVB Leerink
Gilead's remdesivir price gives confidence in revenue, says SVB Leerink
06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
HOLX Hologic
$57.45 /

-0.13 (-0.23%)

07/02/20 Needham
Hologic price target raised to $64 from $60 at Needham
06/30/20 Cowen
Hologic helped by COVID testing, Cowen upgrades to Outperform
06/30/20 Cowen
Hologic upgraded to Outperform from Market Perform at Cowen
06/16/20 BTIG
Hologic price target raised to $60 from $54 at BTIG
MRK Merck
$76.70 /

-1.17 (-1.50%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
OSUR OraSure
$13.86 /

+0.495 (+3.71%)

06/25/20 Lake Street
OraSure initiated with a Buy at Lake Street
04/21/20 Stephens
OraSure resumed with an Equal Weight at Stephens
OSUR OraSure
$13.86 /

+0.495 (+3.71%)

MRK Merck
$76.70 /

-1.17 (-1.50%)

HOLX Hologic
$57.45 /

-0.13 (-0.23%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

BDX Becton Dickinson
$258.57 /

+5.92 (+2.34%)

ABT Abbott
$93.68 /

+1.11 (+1.20%)

  • 03
    Jun
  • 21
    May
MRK Merck
$76.70 /

-1.17 (-1.50%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

ABT Abbott
$93.68 /

+1.11 (+1.20%)

OSUR OraSure
$13.86 /

+0.495 (+3.71%)

MRK Merck
$76.70 /

-1.17 (-1.50%)

HOLX Hologic
$57.45 /

-0.13 (-0.23%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

BDX Becton Dickinson
$258.57 /

+5.92 (+2.34%)

ABT Abbott
$93.68 /

+1.11 (+1.20%)

MRK Merck
$76.70 /

-1.17 (-1.50%)

HOLX Hologic
$57.45 /

-0.13 (-0.23%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

ABT Abbott
$93.68 /

+1.11 (+1.20%)

Yesterday
Hot Stocks
Allergan says FDA approves expanded BOTOX label for spasticity treatment » 18:33
07/09/20
07/09
18:33
07/09/20
18:33
ABBV

AbbVie

$97.93 /

-1.35 (-1.36%)

Allergan, an AbbVie…

Allergan, an AbbVie company, announced that the U.S. Food and Drug Administration approved a supplemental Biologics License Application that supports expanded use of BOTOX for the treatment of spasticity in pediatric patients 2 years of age and older, including those with lower limb spasticity caused by cerebral palsy. This label expansion is based on Allergan and another manufacturer selectively waiving orphan exclusivity marketing rights each company held for the use of their respective neurotoxins in the treatment of pediatric patients with spasticity caused by cerebral palsy. BOTOX was first approved in June 2019 for the treatment of pediatric patients with upper limb spasticity and in October 2019 for the treatment of pediatric patients with lower limb spasticity, excluding spasticity caused by cerebral palsy. BOTOX has not been shown to improve upper extremity functional abilities, or range of motion at a joint affected by a fixed contracture.

ShowHide Related Items >><<
ABBV AbbVie
$97.93 /

-1.35 (-1.36%)

ABBV AbbVie
$97.93 /

-1.35 (-1.36%)

07/07/20 SunTrust
Evolus price target lowered to $6 from $12 at SunTrust
07/06/20 Piper Sandler
Biohaven launch of Nurtec 'continues to impress,' says Piper Sandler
06/29/20 Mizuho
AbbVie price target raised to $110 from $101 at Mizuho
06/26/20 Raymond James
Adverum Biotechnologies downgradedat Raymond James on abicipar CRL
ABBV AbbVie
$97.93 /

-1.35 (-1.36%)

ABBV AbbVie
$97.93 /

-1.35 (-1.36%)

ABBV AbbVie
$97.93 /

-1.35 (-1.36%)

ABBV AbbVie
$97.93 /

-1.35 (-1.36%)

Hot Stocks
Merck Animal Health gets FDA approval of Bravecto Monthly Chews » 16:31
07/09/20
07/09
16:31
07/09/20
16:31
MRK

Merck

$76.70 /

-1.17 (-1.50%)

Merck Animal Health…

Merck Animal Health announced the FDA's approval of BRAVECTO 1-MONTH Chews for dogs and puppies 8 weeks of age and older. The product is administered as a single, monthly flavored chew formulation for treatment and prevention of fleas and treatment and control of ticks. BRAVECTO 1-MONTH is expected to be available in the coming months.

ShowHide Related Items >><<
MRK Merck
$76.70 /

-1.17 (-1.50%)

MRK Merck
$76.70 /

-1.17 (-1.50%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
MRK Merck
$76.70 /

-1.17 (-1.50%)

MRK Merck
$76.70 /

-1.17 (-1.50%)

MRK Merck
$76.70 /

-1.17 (-1.50%)

MRK Merck
$76.70 /

-1.17 (-1.50%)

Hot Stocks
Pfizer pledges $100M to new Antimicrobial Resistance Action Fund » 15:23
07/09/20
07/09
15:23
07/09/20
15:23
PFE

Pfizer

$33.57 /

-0.19 (-0.56%)

, AMGN

Amgen

$252.34 /

+0.74 (+0.29%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, LLY

Eli Lilly

$166.59 /

-2.52 (-1.49%)

, GSK

GlaxoSmithKline

$40.37 /

-0.35 (-0.86%)

, MRK

Merck

$76.99 /

-0.88 (-1.13%)

, MKGAY

Merck KGaA

$0.00 /

+ (+0.00%)

, TEVA

Teva

$11.60 /

+0.21 (+1.84%)

, TAK

Takeda Pharmaceutical

$17.36 /

-0.135 (-0.77%)

, NVO

Novo Nordisk

$65.63 /

-0.23 (-0.35%)

, JNJ

Johnson & Johnson

$143.03 /

-0.21 (-0.15%)

, NVS

Novartis

$87.53 /

-0.585 (-0.66%)

Pfizer (PFE) announced…

Pfizer (PFE) announced earlier it has pledged $100M to the new Antimicrobial Resistance, or "AMR," Action Fund, which launched today, to help address the significant global public health need for new antibiotics due to the rapid rise of antibiotic-resistant infections. "The AMR Action Fund is a ground-breaking collaboration among more than 20 biopharmaceutical companies that aims to bring 2-4 new antibiotics to patients by 2030 through collaboration between pharmaceutical companies, philanthropies, development banks, and multilateral organizations to re-invigorate and accelerate antibiotic development," the company stated. "As the COVID-19 pandemic has shown, we must invest in the development of medicines now so that we are prepared to help prevent the next public health crisis," added Pfizer Chairman and CEO Albert Bourla. Other investors in the AMR Action Fund include Amgen (AMGN), Bayer (BAYRY), Roche (RHHBY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Merck (MRK), Merck KGaA (MKGAY), Teva (TEVA), Takeda Pharmaceutical (TAK), Novo Nordisk (NVO), Johnson & Johnson (JNJ) and Novartis (NVS). Reference Link

ShowHide Related Items >><<
TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

MKGAY Merck KGaA
$0.00 /

+ (+0.00%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
AMGN Amgen
$252.34 /

+0.74 (+0.29%)

07/02/20 Citi
Citi sees 'considerable amount of investor interest' coming back to Amgen
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Mizuho
Amgen patent win worth $5-$12 per share, says Mizuho
07/01/20 Goldman Sachs
Court ruling removes overhang for Amgen, says Goldman Sachs
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/26/20 JPMorgan
Bayer price target raised to EUR 77 from EUR 75 at JPMorgan
06/26/20 Deutsche Bank
Bayer price target raised to EUR 87 from EUR 85 at Deutsche Bank
06/25/20 Morgan Stanley
Bayer price target raised to EUR 88 from EUR 83 at Morgan Stanley
06/25/20 HSBC
HSBC upgrades Bayer to Buy after settlement on most Monsanto cases in U.S.
RHHBY Roche
$0.00 /

+ (+0.00%)

07/03/20 AlphaValue
Roche upgraded to Add from Reduce at AlphaValue
06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

07/09/20 Morgan Stanley
Eli Lilly won't publish Phase 1 COVID antibody data, says Morgan Stanley
06/29/20 Mizuho
Eli Lilly price target raised to $164 from $155 at Mizuho
06/17/20 JPMorgan
Eli Lilly price target raised to $190 from $175 at JPMorgan
GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
MRK Merck
$76.99 /

-0.88 (-1.13%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
MKGAY Merck KGaA
$0.00 /

+ (+0.00%)

05/15/20 Nord/LB
Merck KGaA downgraded to Hold from Buy at Nord/LB
03/06/20 UBS
UBS backs Neutral on Merck KGaA after Q4 results
12/02/19 Goldman Sachs
Merck KGaA reinstated with a Sell at Goldman Sachs
10/04/19 Loop Capital
Entegris price target raised to $51 from $47 at Loop Capital
TEVA Teva
$11.60 /

+0.21 (+1.84%)

07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 William Blair
Pfenex partner CHMP opinion 'material de-risking event,' says William Blair
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

07/06/20 BofA
Novo Nordisk downgraded to Neutral from Buy at BofA
06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
NVS Novartis
$87.53 /

-0.585 (-0.66%)

07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
TEVA Teva
$11.60 /

+0.21 (+1.84%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

MKGAY Merck KGaA
$0.00 /

+ (+0.00%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

Hot Stocks
AstraZeneca reports Brilinta sNDA accepted, granted FDA Priority Review » 06:49
07/09/20
07/09
06:49
07/09/20
06:49
AZN

AstraZeneca

$54.19 /

+0.7 (+1.31%)

AstraZeneca announced the…

AstraZeneca announced the U.S. Food and Drug Administration has accepted a supplemental New Drug Application, or sNDA, and granted Priority Review for Brilinta for the reduction of subsequent stroke in patients who experienced an acute ischemic stroke or transient ischemic attack. The Prescription Drug User Fee Act date, the FDA action date for this supplemental application, is scheduled for the fourth quarter of 2020. Brilinta is approved in more than 110 countries for the prevention of atherothrombotic events in adult patients with acute coronary syndrome and in more than 70 countries for the secondary prevention of cardiovascular events among high-risk patients who have experienced a heart attack. In May 2020, the FDA approved a label update for Brilinta in the U.S. to include the reduction of the risk of a first heart attack or stroke in high-risk patients with coronary artery disease.

ShowHide Related Items >><<
AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

Hot Stocks
Merck: FDA grants priority review for sBLA for Keytruda » 06:47
07/09/20
07/09
06:47
07/09/20
06:47
MRK

Merck

$77.87 /

-0.77 (-0.98%)

Merck announced that the…

Merck announced that the U.S. FDA has accepted and granted priority review for a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma. This sBLA is based on data from the pivotal Phase 3 KEYNOTE-204 trial, in which KEYTRUDA demonstrated a significant improvement in progression-free survival compared to brentuximab vedotin, a current standard of care in this patient population. The FDA has set a Prescription Drug User Fee Act, or target action, date of October 30.

ShowHide Related Items >><<
MRK Merck
$77.87 /

-0.77 (-0.98%)

MRK Merck
$77.87 /

-0.77 (-0.98%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
MRK Merck
$77.87 /

-0.77 (-0.98%)

MRK Merck
$77.87 /

-0.77 (-0.98%)

MRK Merck
$77.87 /

-0.77 (-0.98%)

MRK Merck
$77.87 /

-0.77 (-0.98%)

Hot Stocks
Mylan announces FDA approval for Hulio » 06:37
07/09/20
07/09
06:37
07/09/20
06:37
MYL

Mylan

$16.20 /

+0.09 (+0.56%)

, ABBV

AbbVie

$99.28 /

-0.06 (-0.06%)

Mylan (MYL) and Fujifilm…

Mylan (MYL) and Fujifilm Kyowa Kirin announced that the FDA has approved Hulio, a biosimilar to AbbVie's (ABBV) Humira, for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis, in both prefilled syringe and auto-injector presentations. In accordance with its patent license agreement with AbbVie, Mylan will be able to launch Hulio in the U.S. during July 2023.

ShowHide Related Items >><<
MYL Mylan
$16.20 /

+0.09 (+0.56%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

MYL Mylan
$16.20 /

+0.09 (+0.56%)

06/18/20 Raymond James
Raymond James says Mylan win over Biogen has 'no real apparent financial upside'
06/18/20 Wedbush
Patent ruling 'creates a significant issue' for Biogen, says Wedbush
03/25/20 Cantor Fitzgerald
Few concerns weighing on Mylan shares today, says Cantor Fitzgerald
02/06/20 BMO Capital
Biogen price target raised to $317 from $297 at BMO Capital
ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

07/07/20 SunTrust
Evolus price target lowered to $6 from $12 at SunTrust
07/06/20 Piper Sandler
Biohaven launch of Nurtec 'continues to impress,' says Piper Sandler
06/29/20 Mizuho
AbbVie price target raised to $110 from $101 at Mizuho
06/26/20 Raymond James
Adverum Biotechnologies downgradedat Raymond James on abicipar CRL
MYL Mylan
$16.20 /

+0.09 (+0.56%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

MYL Mylan
$16.20 /

+0.09 (+0.56%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

MYL Mylan
$16.20 /

+0.09 (+0.56%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

MYL Mylan
$16.20 /

+0.09 (+0.56%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

Hot Stocks
Ideaya doses first patient in Phase 1 combination study of IDE196/binimetinib » 06:06
07/09/20
07/09
06:06
07/09/20
06:06
IDYA

Ideaya Biosciences

$13.80 /

+0.32 (+2.37%)

, PFE

Pfizer

$33.76 /

-0.27 (-0.79%)

IDEAYA Biosciences (IDYA)…

IDEAYA Biosciences (IDYA) announced First-Patient-In, or FPI, in the Phase 1 combination study of IDE196 and binimetinib, a MEK inhibitor, in metastatic uveal melanoma, or MUM. IDEAYA said in a release, "The clinical combination of IDE196 and binimetinib is being evaluated by IDEAYA with binimetinib being supplied by Pfizer pursuant to a clinical trial collaboration and supply agreement. In the MUM setting, IDEAYA's clinical development strategy focuses on rational combinations, including MEK, and supporting studies through collaborations, such as the Pfizer (PFE) clinical trial collaboration and supply agreement. IDEAYA's strategic objective is to enhance the clinical activity of IDE196 through potential synergistic combinations. In the non-MUM GNAQ/11 hotspot mutation basket trial, including skin melanoma, IDEAYA will continue to evaluate IDE196 monotherapy and potential combinations, such as with binimetinib. IDEAYA anticipates interim data from the MEK combination study in late 2021 to early 2022, at which time the company will evaluate a potential registrational path for MUM and a potential partnership."

ShowHide Related Items >><<
PFE Pfizer
$33.76 /

-0.27 (-0.79%)

IDYA Ideaya Biosciences
$13.80 /

+0.32 (+2.37%)

IDYA Ideaya Biosciences
$13.80 /

+0.32 (+2.37%)

06/17/20 H.C. Wainwright
Ideaya Biosciences price target raised to $22 from $13 at H.C. Wainwright
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
06/16/20 Oppenheimer
Ideaya Biosciences price target raised to $25 from $17 at Oppenheimer
04/06/20
Fly Intel: Top five analyst initiations
PFE Pfizer
$33.76 /

-0.27 (-0.79%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
PFE Pfizer
$33.76 /

-0.27 (-0.79%)

IDYA Ideaya Biosciences
$13.80 /

+0.32 (+2.37%)

  • 18
    Jun
PFE Pfizer
$33.76 /

-0.27 (-0.79%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

IDYA Ideaya Biosciences
$13.80 /

+0.32 (+2.37%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

Conference/Events
International Aids Society to hold a virtual conference » 04:55
07/09/20
07/09
04:55
07/09/20
04:55
ABT

Abbott

$92.57 /

+0.21 (+0.23%)

, BDX

Becton Dickinson

$252.65 /

+1.24 (+0.49%)

, GILD

Gilead

$75.63 /

-0.84 (-1.10%)

, HOLX

Hologic

$57.58 /

+0.72 (+1.27%)

, MRK

Merck

$77.87 /

-0.77 (-0.98%)

, OSUR

OraSure

$13.36 /

+0.37 (+2.85%)

23rd International AIDS…

23rd International AIDS Virtual Conference: AIDS 2020 will be held on July 6-10. Webcast Link

ShowHide Related Items >><<
OSUR OraSure
$13.36 /

+0.37 (+2.85%)

MRK Merck
$77.87 /

-0.77 (-0.98%)

HOLX Hologic
$57.58 /

+0.72 (+1.27%)

GILD Gilead
$75.63 /

-0.84 (-1.10%)

BDX Becton Dickinson
$252.65 /

+1.24 (+0.49%)

ABT Abbott
$92.57 /

+0.21 (+0.23%)

ABT Abbott
$92.57 /

+0.21 (+0.23%)

07/01/20 Lake Street
Lake Street says Tandem pact with Abbott, coverage news both 'very positive'
06/15/20 Piper Sandler
Abbott approval narrows competitive gap to DexCom, says Piper Sandler
06/11/20 UBS
Abbott's COVID-19 testing positive contributor, says UBS
06/09/20 Barrington
Surmodics price target raised to $62 from $56 at Barrington
BDX Becton Dickinson
$252.65 /

+1.24 (+0.49%)

07/09/20 Barclays
Becton Dickinson upgraded to Overweight from Equal Weight at Barclays
07/02/20 Wells Fargo
Becton rallies after Wells says rapid COVID test may come very soon
07/02/20 Wells Fargo
Becton rapid antigen COVID test may be available very soon, says Wells Fargo
06/25/20 Raymond James
Becton Dickinson price target lowered to $265 from $290 at Raymond James
GILD Gilead
$75.63 /

-0.84 (-1.10%)

06/30/20 SVB Leerink
Gilead's remdesivir price gives confidence in revenue, says SVB Leerink
06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
06/29/20 RBC Capital
RBC says HIV, other franchises more critical drivers of Gilead than remdesivir
HOLX Hologic
$57.58 /

+0.72 (+1.27%)

07/02/20 Needham
Hologic price target raised to $64 from $60 at Needham
06/30/20 Cowen
Hologic helped by COVID testing, Cowen upgrades to Outperform
06/30/20 Cowen
Hologic upgraded to Outperform from Market Perform at Cowen
06/16/20 BTIG
Hologic price target raised to $60 from $54 at BTIG
MRK Merck
$77.87 /

-0.77 (-0.98%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
OSUR OraSure
$13.36 /

+0.37 (+2.85%)

06/25/20 Lake Street
OraSure initiated with a Buy at Lake Street
04/21/20 Stephens
OraSure resumed with an Equal Weight at Stephens
OSUR OraSure
$13.36 /

+0.37 (+2.85%)

MRK Merck
$77.87 /

-0.77 (-0.98%)

HOLX Hologic
$57.58 /

+0.72 (+1.27%)

GILD Gilead
$75.63 /

-0.84 (-1.10%)

BDX Becton Dickinson
$252.65 /

+1.24 (+0.49%)

ABT Abbott
$92.57 /

+0.21 (+0.23%)

  • 03
    Jun
  • 21
    May
MRK Merck
$77.87 /

-0.77 (-0.98%)

GILD Gilead
$75.63 /

-0.84 (-1.10%)

ABT Abbott
$92.57 /

+0.21 (+0.23%)

OSUR OraSure
$13.36 /

+0.37 (+2.85%)

MRK Merck
$77.87 /

-0.77 (-0.98%)

HOLX Hologic
$57.58 /

+0.72 (+1.27%)

GILD Gilead
$75.63 /

-0.84 (-1.10%)

BDX Becton Dickinson
$252.65 /

+1.24 (+0.49%)

ABT Abbott
$92.57 /

+0.21 (+0.23%)

MRK Merck
$77.87 /

-0.77 (-0.98%)

HOLX Hologic
$57.58 /

+0.72 (+1.27%)

GILD Gilead
$75.63 /

-0.84 (-1.10%)

ABT Abbott
$92.57 /

+0.21 (+0.23%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.